Related Experiment Video
Updated: Mar 7, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Methotrexate Toxicity Management in Polymyalgia Rheumatica: A Case Report.
Devi M Kotharu1, Sai D Vutukuru1, Prafullkumar Patel2
1Department of Medicine, MNR Medical College, Hyderabad, India.
Low-dose methotrexate, a common treatment for autoimmune diseases, can rarely cause severe pancytopenia. Prompt identification and monitoring are crucial for managing methotrexate toxicity and ensuring patient safety.
Area of Science:
- Pharmacology
- Rheumatology
- Hematology
Background:
- Methotrexate (MTX) is an anti-folate medication with anti-inflammatory and anti-proliferative effects.
- Low-dose MTX (10-25 mg/week) is a standard, safe, and effective therapy for autoimmune conditions.
- While generally safe, MTX toxicity can manifest as severe complications, including pancytopenia.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis IV: Nursing Management
Rheumatic Heart Disease IV: Nursing Management